Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
US FDA Accepts Regulatory Submissions for Review of Tafamidis to Treat Transthyretin Amyloid Cardiomyopathy
Pfizer Inc. announced today that the US Food and Drug Administration (FDA) accepted for filing the company’s New Drug Applications (NDAs) for tafamidis for the treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM). Pfizer has submitted two NDAs based on two forms of Tafamidis: meglumine salt and free acid. Tafamidis is the only product to complete a Phase 3 trial evaluating its efficacy, safety, and tolerability in patients with ATTR-CM, a rare, fatal, and underdiagnosed condition.
The Tafamidis meglumine form (20 mg capsule) has been granted Priority Review. The FDA grants Priority Review to medicines that may offer significant advances in treatment or may provide a treatment where no adequate therapy exists. The target Prescription Drug User Fee Act (PDUFA) action date for a decision by the FDA is in July 2019.
myBinderRelated Content
-
Transthyretin Amyloid Cardiomyopathy (ATTR-CM): What you Need to Know About This Rare Heart Conditionhttps://www.youtube.com/watch?v=QLOyVUaz...
-
Ronglih Liao, PhDRonglih Liao is Co-Director of the Stanf...
-
U.S. FDA Approves VYNDAQEL® and VYNDAMAX™ for Use in Patients with Transthyretin Amyloid Cardiomyopathy, a Rare a...Pfizer Inc. announced today that the U.S...
-
Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid CardiomyopathyBackground: Tafamidis is approved in ma...
-
Transthyretin Cardiac Amyloidosis: An Under-Diagnosed Cause of Heart FailureIntroduction: Cardiac amyloidosis is th...
-
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CMThe 30-month results of the phase 3 ATTR...
-
Newer Therapies for Amyloid CardiomyopathyThe heart and the kidneys are the most c...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
